Sign in

You're signed outSign in or to get full access.

Hsin-Hui Miao

Independent Director at ABVC BIOPHARMA
Board

About Hsin-Hui Miao

Independent Director of ABVC. Age 59. Background in education administration and operations; Bachelor of Education, Taichung University of Education (1998). Nominated for re‑election in 2025; designated as independent under Nasdaq rules and serves on Audit, Compensation, and Corporate Governance & Nominating Committees .

Past Roles

OrganizationRoleTenure/DatesCommittees/Impact
Affiliated High School of Tunghai University, Kindergarten DivisionKindergarten teacher; leader of general affairs teamAug 1988 – Jul 2021School operations/general affairs leadership
Yueh Shan Chi Cram SchoolCounter ManagerAug 2021 – May 2022Front-office management

External Roles

OrganizationRoleTenure/DatesNotes
No other public company directorships disclosed for Miao .

Board Governance

  • Independence: Board determined Miao is an “independent director” under Nasdaq rules .
  • Committee assignments (no chair roles):
    • Audit Committee member (Chair: Yen‑Hsin Chou; Chou designated “audit committee financial expert”) .
    • Compensation Committee member (Chair: Norimi Sakamoto) .
    • Corporate Governance & Nominating Committee member (Chair: Yoshinobu Odaira) .
  • Attendance: Director/committee meeting attendance rates not disclosed in the latest proxy (no explicit attendance table located) .
  • Board context and oversight load:
    • March 2025: Company and Audit Committee concluded FY2023 financial statements required restatement; disclosure controls deemed not effective (material weakness) .
    • CFO resigned Mar 5, 2025; CEO serving as interim CFO, increasing Audit Committee oversight demands .

Fixed Compensation

ElementAmount/DetailPolicy/Notes
Director cash retainerNot specified in 2024/2025 proxyLatest proxy does not disclose director cash fee amounts .
Historical disclosure (context)Intended $3,500 monthly per director (from 2022 proxy)Forward‑looking intent disclosed in 2022; not reaffirmed in 2025 proxy .

Performance Compensation

YearInstrumentGrant DetailVesting/TermNotes
2024Stock options to directorsNoneCompany disclosed it did not pay stock options to directors in FY2024 .
2022 (company‑level program)Stock options to 5 directorsAggregate 76,190 options (post‑split) at $30.00 exercise price (post‑split) on Apr 16, 2022Fully vested at grant; 10‑year termDisclosed at company level; individual recipients not listed .

No director RSU/PSU program or performance metrics for director pay are disclosed in the latest proxy .

Other Directorships & Interlocks

DirectorOther Public BoardsInterlocks/Relationships
Hsin‑Hui MiaoNone disclosedBoard states no relationships requiring Item 404 disclosure for directors, with related‑party items separately identified (e.g., land proposal involves another director, not Miao) .

Expertise & Qualifications

  • Education: Bachelor of Education, Taichung University of Education (1998) .
  • Domain experience: Long tenured education administration/operations; no financial expert designation (Audit Committee financial expert is Chou) .

Equity Ownership

HolderShares Beneficially Owned% of ClassReference DateShares Outstanding
Hsin‑Hui Miao41,505<1%April 28, 202516,153,055

No footnotes indicate pledging; no hedging/pledging policy disclosure specific to directors was identified in the proxy section searched .

Governance Assessment

  • Independence and workload: Miao is independent and serves on all three key committees, which centralizes governance workload for an individual with a career background outside finance; Audit Committee financial expertise rests with the chair (Chou) .
  • Control environment stressors: 2025 restatement determination and material weakness plus CFO vacancy elevate risk oversight demands on Audit Committee members, including Miao .
  • Shareholder engagement signal: The January 16, 2024 annual meeting failed to reach quorum and was adjourned, a negative signal on shareholder engagement and process that the board should remediate .
  • Related‑party environment: Board considered a director‑related land transaction in 2024 (subsequently terminated); while not implicating Miao, such proposals heighten the need for rigorous independent committee oversight .
  • Director compensation alignment: No director option grants in FY2024; recent history shows sporadic director option grants (notably in 2022). Lack of disclosed annual equity/fee structure in 2025 limits visibility into ongoing alignment mechanisms .

RED FLAGS

  • Financial reporting: Restatement of 2023 financials; disclosure controls not effective (material weakness) .
  • Finance leadership continuity: CFO resignation with CEO acting as interim CFO .
  • Shareholder process: No quorum at 2024 annual meeting; meeting adjourned .
  • Related‑party proposals: Proposed issuance of stock to acquire land from director (terminated) underscores conflict risk requiring vigilant independent oversight .

Equity Ownership (Detail Table Extract)

NameShares% of Class
Hsin‑Hui Miao41,505<1%

As of April 28, 2025, ABVC had 16,153,055 shares outstanding .